China's National Medical Products Administration (NMPA) is one of the world's largest medical device regulators and operates an entirely distinct framework from the EU Medical Device Regulation. A CE certificate under Regulation (EU) 2017/745 does not confer any market access in China. Entering the Chinese market requires a separate NMPA registration pathway, a mandatory local agent, Chinese-language documentation, often in-country testing and clinical data, and a QMS that withstands an NMPA-style inspection. For EU startups, China is rarely the right second market after CE marking — it is a deliberate, capital-intensive strategic choice that belongs later in the sequencing, not earlier.

By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.

TL;DR

  • The NMPA (National Medical Products Administration) is China's central medical device regulator. Its framework is independent from the EU MDR, the US FDA, and all other jurisdictions — a CE certificate has no standing in China.
  • NMPA classifies medical devices into three classes, broadly by risk, but the class boundaries and the conformity pathways do not map one-to-one onto MDR Annex VIII classes.
  • A local Chinese legal agent is mandatory for any foreign manufacturer placing a device on the Chinese market. The agent carries real regulatory and liability responsibilities that must be understood before signing.
  • Clinical evaluation expectations in China frequently differ from the EU model. In-country clinical data and in-country type testing have historically been significant cost and calendar drivers for foreign manufacturers.
  • For most EU startups, the right moment to enter China is not immediately after CE marking. It is after EU revenue is real, a China commercial partner is named, and the capital for a multi-year registration effort is committed.

Why China shows up in every startup deck — and why that is a warning sign

China appears in almost every MedTech investor deck we have reviewed. It appears as a row in the "future markets" slide, as a bullet in the international expansion section, and often as a large unqualified market-size number next to an optimistic entry date. In the vast majority of those decks, the team has not yet spoken to a Chinese regulatory advisor, has no named local partner, and has no line item in the budget for the actual cost of a Chinese registration.

The gap between "China is in the plan" and "China is actually on the path" is wider for the NMPA than for almost any other jurisdiction a European startup will consider. The framework is distinct, the language is a genuine barrier, the local agent requirement creates a commercial dependency that has to be structured carefully, and the evidence expectations have historically been heavier than most EU founders assume going in.

This post covers what EU founders should know about the NMPA at the general framing level — enough to make a sound sequencing decision and to ask a Chinese regulatory advisor the right questions. It is not a registration manual. For current, specific, actionable Chinese regulatory parameters, a Chinese regulatory partner is not optional. It is the gate.

NMPA at the general framing level

The NMPA is the central regulatory authority responsible for medical devices, drugs, and cosmetics in China. For medical devices specifically, it operates a registration and post-market oversight framework with its own technical requirements, testing expectations, clinical evaluation rules, and QMS inspection regime. The framework evolves — China has been actively modernising its medical device regulation in recent years — and any specific procedural claim should be verified against the current NMPA guidance at the time of the registration effort.

Three general-framing facts matter for EU startups making a sequencing decision:

  1. The NMPA framework is entirely separate from the MDR. A CE certificate is a useful supporting document in some contexts but it does not grant any form of automatic recognition or expedited pathway in China.
  2. Medical devices are classified into three risk-based classes, with different registration pathways for each class and distinct pathways for domestic versus imported devices. The class assignment, and therefore the pathway, depends on NMPA's own classification catalogue, which does not always agree with the MDR Annex VIII outcome for the same device.
  3. Post-market obligations — vigilance, adverse event reporting, label and instruction updates, re-registration on a defined cycle — continue for the entire time the device is on the Chinese market. The registration is not a one-time cost.

For specific current procedural details, timelines, fee structures, and document templates, the authoritative source is the NMPA itself and a qualified Chinese regulatory advisor. This post deliberately stays at the general framing level because the rules move and the cost of citing outdated specifics is higher than the value of false precision.

Classification differences from the MDR

The MDR classifies medical devices into four classes — I, IIa, IIb, and III — using the 22 rules in Annex VIII of Regulation (EU) 2017/745, under Article 51. The NMPA classifies medical devices into three risk-based classes using its own classification catalogue and its own definitional framework for invasiveness, duration of use, and intended purpose.

For EU startups, the operational implication is simple and painful: you cannot assume that your MDR class maps cleanly onto an NMPA class. A device that your Notified Body treated as Class IIa under MDR Rule 11 may land in a different NMPA class with a different registration pathway, different documentation expectations, and different testing requirements. The mapping is a question for a Chinese regulatory advisor and the current NMPA classification catalogue, not a question that can be answered from the MDR file alone.

The practical move in an expansion sequencing conversation is to stop assuming the class carries across and start treating the China classification question as its own work package. The work package has a specific deliverable: a written classification opinion from a Chinese regulatory advisor, tied to the current NMPA catalogue, identifying the registration pathway and the expected evidence set. Until that document exists, the China line in the deck is an estimate, not a plan.

The local agent requirement

Foreign manufacturers cannot register a medical device directly with the NMPA. A Chinese legal agent — a local entity established in China — is required to act as the point of contact between the manufacturer and the NMPA, to hold certain registration-related responsibilities, and to support post-market obligations including adverse event reporting and communication with the authority.

The local agent is not a formality. The agent is a real commercial and regulatory counterparty whose competence, capacity, and alignment with the manufacturer's interests matter enormously. A good agent adds material value: local language competence, familiarity with current NMPA expectations, support through testing and clinical work, and a relationship with the authority that smooths the inevitable questions. A bad agent is a source of delay, cost, and risk — up to and including the risk of losing registration continuity if the relationship breaks down.

The agent relationship has to be structured with the same care as any other critical supplier relationship. That means a written contract covering scope, fees, termination, data handling, IP protection, transfer of registration in the event of termination, and the division of responsibilities for post-market obligations. Startups that treat the agent appointment as an administrative step rather than a strategic decision regularly discover, months later, that the agent is the bottleneck and the exit path is not clean.

For the general framing of local representative roles across jurisdictions, see post 626.

Clinical evaluation expectations

Clinical evaluation under the MDR follows Article 61 and Annex XIV and can draw on literature, equivalence, and new clinical investigation under the conditions set out in the Regulation. NMPA has its own clinical evaluation framework, with its own list of device types that may be exempted from clinical trials, its own rules on when foreign clinical data can be used to support a Chinese registration, and its own expectations about in-country clinical data for certain device categories.

The general-framing point for EU startups is that foreign clinical data does not automatically satisfy Chinese clinical requirements. Whether EU or US clinical data can be leveraged depends on the device category, the specific study design, the population, and the current NMPA acceptance criteria. For some device types the foreign data carries significant weight. For other device types the expectation is effectively in-country work.

The decision of whether to rely on existing clinical evidence or to plan in-country clinical work is a major cost and calendar driver. It is the kind of decision that has to be made early in the sequencing conversation, because the answer determines whether China is a 12-month project or a multi-year one. A Chinese regulatory advisor can tell you where your specific device falls. Assumptions from the EU side alone are unreliable.

Manufacturing and QMS considerations

EU manufacturers placing devices on the European market operate a QMS under EN ISO 13485:2016+A11:2021, which provides presumption of conformity with MDR QMS obligations under Article 10(9). NMPA has its own QMS expectations and its own inspection regime for manufacturing sites, which may include on-site inspections of the manufacturer's facilities by NMPA inspectors for certain device classes and pathways.

For a startup that already runs a mature EN ISO 13485-based QMS, the core of the quality system is the same everywhere — document control, design controls, risk management, CAPA, training, supplier controls, post-market surveillance. What changes across jurisdictions is the overlay of country-specific documentation, reporting pathways, and inspection expectations. China's overlay is substantial and has historically included elements that EU manufacturers do not encounter in a Notified Body audit.

The planning implication is that the QMS investment made for the MDR is a starting point, not a finishing point. The gap analysis between the current QMS and NMPA expectations is its own work package, and it should be scoped by a Chinese regulatory advisor, not estimated from a European desk.

Timeline and cost framing

We stay at the general framing level on timeline and cost because specific numbers move, and a wrong number in a published post is worse than no number. The framing that holds:

  • China registration is not fast. The end-to-end timeline from decision to first sale is measured in multiple calendar quarters to multiple years, depending on class, evidence strategy, and whether in-country testing or clinical work is required.
  • China registration is not cheap. The cost stack includes the local agent fee, testing, translation, regulatory advisory, possibly clinical work, registration fees themselves, QMS gap work, and the ongoing post-market costs. For most device categories, the total significantly exceeds what EU founders assume when they first put "China" on the expansion slide.
  • Registration is time-bounded. Devices must be re-registered on a defined cycle, which introduces a recurring renewal cost line that many business plans forget.

For current specific timelines and fee structures, ask a Chinese regulatory advisor for a written estimate against your specific device and classification. Any number in a blog post will be wrong by the time it is read.

Common mistakes EU startups make with China

  • Treating China as a single line in the expansion deck without talking to a Chinese regulatory advisor. The gap between the deck bullet and the real cost is the widest of any major market.
  • Assuming the MDR class transfers to NMPA classification. The classification catalogues are independent. Work the China classification as its own question.
  • Treating the local agent appointment as an administrative step. The agent is a strategic counterparty with real power over the registration. Structure the relationship accordingly.
  • Assuming EU clinical data will carry the registration. Sometimes it does. Sometimes it does not. The answer depends on device type and current NMPA acceptance. Plan for both scenarios until you know which one applies.
  • Sequencing China as the second market after CE marking without commercial readiness. A Chinese registration without a Chinese commercial partner is a registration sitting on a shelf.
  • Budgeting the registration as a one-time cost. Re-registration cycles, ongoing post-market obligations, and local agent fees are recurring line items.
  • Copying a competitor's China timeline. The competitor's device is not your device, their evidence is not your evidence, and their agent relationship is not your agent relationship. Their timeline is not your timeline.

The Subtract to Ship angle on China

The Subtract to Ship framework applied to expansion sequencing says: every market in the plan must earn its place by tracing to a specific commercial reality, not to an ambition. Applied to China, the test is honest and uncomfortable.

Is there a named Chinese commercial partner? Is there a Chinese clinical champion? Is there capital committed to a multi-quarter or multi-year registration effort on top of the existing MDR spend? Is the runway long enough that the Chinese registration can be completed before the current funding round runs out? Is there a reason this company is entering China in this sequencing position rather than later?

If the answers are vague, the subtraction move is to take China out of the current sequencing step and put it back on the strategic horizon as a future market — named, budgeted, and sequenced for the right moment, but not the next step. Subtracting China from the immediate plan is not a failure. It is the discipline that frees capital and attention for the markets that are actually ready. For the full treatment of the sequencing logic, see post 636. For the methodology itself, see post 065.

Reality Check — Is China really in your plan?

  1. Have you spoken to at least one qualified Chinese regulatory advisor about your specific device, or is your China plan based on general reading?
  2. Do you have a written classification opinion tied to the current NMPA catalogue, or are you assuming the MDR class carries across?
  3. Do you have a named or shortlisted local agent, and have you reviewed the commercial terms of that relationship with legal counsel?
  4. Have you scoped — in writing — whether your existing clinical data is likely to satisfy NMPA expectations, or whether in-country clinical work is probable?
  5. Is the full China cost, including recurring re-registration and post-market obligations, in the budget, or only the first submission fee?
  6. Does the China timeline in your deck match the timeline a Chinese regulatory advisor would give you for your specific device, or is it a placeholder?
  7. If you removed China from the sequencing entirely, what would actually change in the business in the next 18 months? If the answer is "nothing material," why is it still in the sequencing?

If more than three of these produced a "not yet," China is an aspiration in your plan, not a sequenced market. The honest move is to name it as such.

Frequently Asked Questions

Does a CE certificate under the MDR help with NMPA registration? A CE certificate is sometimes relevant as a supporting document in an NMPA submission, but it does not grant automatic recognition or an expedited pathway. The Chinese registration is its own submission under its own rules, and the CE certificate does not substitute for the NMPA-required evidence set. The practical impact varies by device class and current NMPA expectations.

Do I need a local agent in China? Yes. Foreign manufacturers cannot register a medical device directly with the NMPA. A Chinese legal agent is required, and the agent's role includes regulatory communication, post-market reporting, and ongoing interaction with the authority. Choosing the right agent is one of the most consequential decisions in the China entry path.

How does NMPA classify medical devices compared to the MDR? NMPA uses a three-class risk-based system, distinct from the four-class MDR system under Article 51 and Annex VIII. The classification catalogues are independent, and a device's class under NMPA must be determined from the NMPA catalogue directly. Assuming the MDR class carries over is a common error.

Will my existing EU clinical data satisfy NMPA requirements? It depends on the device category and the specific NMPA expectations at the time of submission. For some device types foreign clinical data can carry significant weight. For others, in-country clinical work is effectively expected. A Chinese regulatory advisor can give you a device-specific answer.

When is the right time for an EU startup to enter China? Rarely immediately after CE marking. For most startups, the right sequencing puts China after the EU launch is stable, after a first non-EU market has validated the international expansion capability, and only when a named Chinese commercial partner and committed capital are in place. China as an early second market after CE is usually a mistake.

Where should I get current specific NMPA procedural information? From the NMPA directly and from a qualified Chinese regulatory advisor. Published blog posts — including this one — should be treated as orientation, not as procedural guidance. Specifics move, and the cost of acting on outdated specifics is real.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices (MDR), Article 2 (definitions), Article 51 and Annex VIII (classification). Official Journal L 117, 5.5.2017. Cited here as the EU comparison baseline — the authoritative framework for EU market access and the framework against which NMPA is contrasted in this post.
  2. EN ISO 13485:2016 + A11:2021 — Medical devices — Quality management systems — Requirements for regulatory purposes. The QMS standard that forms the starting point for any multi-market regulatory work, including the gap analysis against NMPA expectations.
  3. China's National Medical Products Administration (NMPA) — referenced throughout this post at the general framing level only. The authoritative source for current specific procedural details, timelines, fees, classification catalogue entries, clinical data expectations, and QMS inspection rules is the NMPA itself, together with current guidance from a qualified Chinese regulatory advisor. This post deliberately does not cite specific NMPA decree or order numbers because Chinese medical device regulation evolves and outdated specifics in a published blog post do more harm than good.

Explicit expertise boundary: Zechmeister Strategic Solutions is an EU MDR practice. Our authoritative expertise is the MDR and the adjacent European regulatory landscape. On China and the NMPA, this post is orienting-level content intended to help EU founders make sound sequencing decisions and ask qualified Chinese regulatory advisors the right questions. It is not a substitute for Chinese regulatory counsel, and no reader should treat it as one. For a China registration effort, engage a qualified Chinese regulatory advisor with a current track record in your specific device category.

This post is part of the FDA & International Market Access series in the Subtract to Ship: MDR blog. Authored by Tibor Zechmeister and Felix Lenhard. China is one of the markets where the gap between the slide and the reality is widest. Respecting that gap — and sequencing accordingly — is not pessimism. It is the same discipline the rest of this blog applies to every other regulatory decision.